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doi:10.1016/j.jmii.2010.02.005Background: Allergic rhinitis (AR) often coexists with and can significantly worsen bronchial
asthma (BA). We evaluated the proportion of patients with BA and concomitant AR (BAþ AR)
diagnosed and treated in an average clinical practice.
Methods: A cross-sectional study methodology was used to determine the prevalence of AR in
patients more than 15 years of age with a documented history of asthma who experienced
wheezing during the prior 12 months. The International Study of Asthma and Allergies in Child-
hood standardized written questionnaire was used and therapeutic class choices were
recorded.
Results: Among 750 surveyed asthma patients, 524 patients (69.9%) experienced AR. Of those
with BA and AR, there were 44 patients (8.4%) who were not diagnosed with AR, and the treat-
ment rate for AR was 62.1%. The most frequent severity level of BA and AR were moderate
persistent (38.9%) and intermittent mild (52.5%), respectively. There were no significant
differences between patients with AR and without AR.of Internal Medicine, Kaohsiung Medical University Chung-Ho Memorial Hospital, 100 Tzyou 1st Road,
tw (M.-S. Huang).
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140 S.-M. Tsao et al.Conclusions: The prevalence of AR in patients with asthma was 69.9% in this study. Despite
Allergic Rhinitis and its Impact on Asthma guideline recommendations encouraging evaluation
and treatment of AR among asthmatics, nearly 8.4% of asthmatics with AR were undiagnosed,
and 37.9% of asthmatics with AR were untreated for AR.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Allergic rhinitis (AR) is often a comorbid condition seen with
bronchial asthma (BA), and it has been proposed to be
a marker for the presence of more difficult to control
asthma.1e3 Some experts believe that they are likely the
manifestations of the same syndrome of allergic origin
because of their pathophysiological similarities. Evidence
for this link has not only mainly been found through clinical
observations and epidemiological studies but also from
immunological observations and therapy outcomes.4,5 This
concept has been labeled “one airway, one disease”6 or
“united airways disease.”7 In addition, the management of
asthma and AR have been closely correlated because of the
impact on both health care costs and asthma outcome.8
Thus, Allergic Rhinitis and its Impact on Asthma (ARIA)
guidelines recommend that patients with asthma should be
evaluated for the presence of AR and a combined treat-
ment strategy for asthma and AR be administered.9
However, there are only a few epidemiologic reports in
the English literature regarding the prevalence of BA in AR
in Asian countries compared with abundant data in Western
countries.
Evaluation and control of AR in patients with asthma,
initiated in 2006, is a nationwide surveillance study
designed to determine the prevalence of AR in patients
with asthma in Taiwan. To achieve a better understanding
of the association of BA and AR in an Asian country, we
conducted this study to evaluate the prevalence of AR in
Taiwanese patients with asthma who receive regular
asthma treatment and to investigate whether those
patients diagnosed with AR have been treated for AR.
Patients and methods
A nationwide sample of nine hospitals was selected for
conducting the study, including three medical centers and
six regional hospitals, distributed from north to south
Taiwan. Patients more than 15 years of age with a docu-
mented history of asthma who experienced wheezing
during the past 12 months were enrolled in this study. This
study was approved by the Institute Review Board in each
hospital. And all signed consent forms of patients were
obtained when patients participated. Patients with chronic
obstructive pulmonary disease, congenital heart diseases,
and severe respiratory diseases other than asthma were
excluded.
Subjects were outpatients who visited hospitals for their
asthma treatment, all procedures were conducted in
a single visit, and patient medical records were reviewed.
Subjects were interviewed face-to-face at clinic and the
International Study of Asthma and Allergies in Childhood(ISAAC)10 standardized written questionnaire was used to
identify symptoms of asthma and AR. Severity of asthma
and AR were evaluated based on Global Initiative for
Asthma guidelines11 and ARIA guidelines, respectively.9
Therapeutic class choice was recorded.
Statistical analyses
The proportion of patients with BA and those with
concomitant AR were determined. Results are presented as
mean standard deviation. The means of two groups were
analyzed by Student t test and the data of subgroup were
analyzed by Chi-square test. The statistical significance was
determined by a p value lesser than 0.05. All statistical
analyses were performed using the SAS software, version
9.1 (SAS Institute, Cary, NC, USA).
Results
From November 1, 2006 to October 31, 2007, a total 750
asthma patients were recruited. The age distribution,
gender, years with asthma diagnosis, and severity of BA and
AR were recorded (Table 1). The average patient age was
50.6 17.4 years old; 42.3% were male. There were no
significant differences between patients with AR and
without AR, except for age. The patient group with AR
seemed to be younger than those without AR (48.7
17.1 years vs. 55.1 17.5 years; p< 0.05).
Among the 750 asthma patients, 524 patients (69.9%)
experienced sneezing or a runny or blocked nose without
a cold or the flu during the 12 months before evaluation.
For most patients (480/524, 91.6%), the diagnosis of AR had
been made concomitant with BA. However, there were 44
patients (8.4%) who were not diagnosed with AR, although
they had reported AR symptoms. The distribution of
severity of asthma and drugs used to treat BA and AR are
presented in Tables 2e4, respectively. The mean years of
asthma diagnosis was 11.6 14.6. The most frequent level
of BA severity was moderate persistent (38.9% overall,
39.5% in patients with AR, and 37.2% in patients without
AR), followed by mild persistent (26.8% overall, 26.7% in
patients with AR, and 27.0% in patients without AR),
intermittent (19.1% overall, 19.5% in patients with AR, and
18.1% in patients without AR), and severe persistent (15.3%
overall, 14.3% in patients with AR, and 17.7% in patients
without AR). There was no significant difference between
patients with AR and without AR. The frequencies of AR
severity were intermittent mild (52.5%), intermittent
moderate-severe (24.3%), persistent mild (11.9%), and
persistent moderate-severe (11.3%). The mean years of AR
diagnosis was 14.8 16.3; 303 patients (63.1%) had
seasonal-type AR, and 177 patients (36.9%) had perennial
Table 1 Patient characteristics
Patients with asthma diagnosis With AR (nZ 524) Without AR (nZ 226) Total (nZ 750)
Agea 48.7 17.1 55.1 17.5 50.6 17.4
Gender
Female, n (%) 306 (58.4) 127 (56.2) 433 (57.7)
Male, n (%) 218 (41.6) 99 (43.8) 317 (42.3)
Smoking status
Never smoked, n (%) 387 (73.8) 156 (69.0) 543 (72.4)
Past smoker, n (%) 81 (15.5) 36 (15.9) 117 (15.6)
Current smoker, n (%) 56 (10.7) 34 (15.1) 90 (12.0)
a p< 0.05 by the t test to assess mean between two groups.
ARZ allergic rhinitis.
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treating BA was a fixed dose combination of inhaled corti-
costeroid and long-acting b2 agonist, and most patients
were treated with four and more therapies combined. Most
patients had their AR with an oral H1 blocker (61.0%) fol-
lowed by a leukotriene antagonist (31.3%). The treatment
rate for AR in patients with BA and AR patients was 62.1%.Discussion
Epidemiologic studies have suggested that asthma and AR
often coexist in the same patient. A recent survey
demonstrated that 20e40% of patients with AR have
asthma, and 30e90% patients with asthma have AR.3 TheTable 2 Asthma evaluation
Patients with asthma diagnosis With AR (nZ 524
Years with asthma diagnosis 11.5 14.3 (nZ
Asthma severity
Intermittent 102 (19.5)
Mild persistent 140 (26.7)
Moderate persistent 207 (39.5)
Severe persistent 75 (14.3)
Asthma treatment 519 (99.1)
Single therapya 68 (13.1)
Two combined therapies 160 (30.8)
Three combined therapies 127 (24.5)
Four and more combined therapies 164 (31.6)
Therapy combinations
Fixed dose combination of ICSþ LABAb 362 (69.7)
Sustained-release theophyllineb 235 (45.3)
Leukotriene modifier 150 (28.9)
Oral glucocorticosteroidb 137 (26.4)
Inhaled glucocorticosteroidb 98 (18.9)
LABA 59 (11.4)
LABA 42 (8.1)
Otherb 40 (7.7)
a p< 0.05 by Chi-square test for the distribution of treatment (si
therapies) in two group (with AR vs. without AR)
b p< 0.05 by the t test to assess mean between two groups (with A
Data are presented as mean standard or n(%).
ARZ allergic rhinitis; ICSZ inhaled corticosteroid; LABAZ long-actinobserved prevalence of AR in patients with asthma varies
considerably throughout the world. A literature review
indicated 50e100% prevalence of AR in patients with
allergic asthma in the United States and in Europe.2
However, the prevalence of AR in patients with asthma
was estimated at only 6.2% in a single study from China.12
There are at least two factors that may explain the
discrepancy in reported prevalence between studies. First,
different source criteria were applied across studies,
including sampling population, age profiles, and methods
used to collect the data. Second, the diagnostic criteria
used to define asthma and AR were not standardized
across the published articles. Therefore, a standardized
questionnaire, the ISAAC, was developed and has been used
worldwide for the past decade to generate a reliable global) Without AR (nZ 226) Total (nZ 750)
523) 11.8 15.5 (nZ 225) 11.6 14.6 (nZ 748)
41 (18.1) 143 (19.1)
61 (27.0) 201 (26.8)
84 (37.2) 291 (38.9)
40 (17.7) 115 (15.3)
226 (100) 745 (99.3)
19 (8.4) 87 (11.7)
46 (20.4) 206 (27.6)
66 (29.2) 193 (25.9)
95 (42.0) 259 (34.8)
177 (78.3) 539 (72.3)
133 (58.8) 368 (49.4)
51 (22.6) 201 (27.0)
81 (35.8) 218 (29.3)
27 (11.9) 125 (16.8)
18 (8.0) 77 (10.3)
19 (8.4) 61 (8.2)
43 (19.0) 83 (11.1)
ngle, two combined, three combined, four and more combined
R vs. without AR).
g b2 agonist.
Table 3 Allergic rhinitis evaluation
Asthma patients (nZ 750)
Asthma patient with allergic
rhinitis symptom
524 (69.9)
The severity of allergic rhinitis nZ 522
Intermittent mild 274 (52.5)
Persistent mild 62 (11.9)
Intermittent moderate-severe 127 (24.3)
Persistent moderate-severe 59 (11.3)
Diagnosed with allergic rhinitis 480 (91.6)
Years of allergic rhinitis (nZ 479) 14.8 16.3
Type
Seasonal 303 (63.1)
Perennial with seasonal
exacerbation
177 (36.9)
Data are presented as n(%) or mean  standard deviation.
142 S.-M. Tsao et al.map of prevalence.13 Utilizing the ISAAC questionnaire in
the present study, the percentage of patients with AR
among all patients with BA was 69.9%. This result was
similar to the prevalence of 73% reported in an interna-
tional survey of comorbid asthma and AR published by
Valovirta and Pawankar.3 However, our results were higher
than from recent studies in Europe (60%) and from Japan
(52.4%).14,15
In previous publications, age has always been a signifi-
cant factor influencing the prevalence and impact of
concomitant AR in people with asthma.15 The frequency of
AR in asthma decreases with increasing age. Although we
have focused our analysis on adult patients, the present
findings are consistent with those of previous reports in that
asthma patients with AR were younger than those without
AR. More than two-thirds of the patients included in this
survey were already experiencing AR symptoms when theTable 4 Distribution of allergic rhinitis treatment in asthma pa
Patients with asthma diagnosis With AR (nZ
Treatments 326 (62.1)
Single therapy 221 (67.8)
Two combined therapies 78 (23.9)
Three combined therapies 25 (7.7)
Four and more combined therapies 2 (0.6)
Therapy combinations
Oral H1 blocker 199 (61.0)
Leukotriene modifier 102 (31.3)
Oral decongestant 64 (19.6)
Nasal glucocorticosteroid 50 (15.3)
Nasal decongestant 12 (3.7)
Oral glucocorticosteroid 15 (4.6)
Nasal H1 blocker 1 (0.3)
Nasal ipratropium 0 (0.0)
Other 17 (5.2)
Data are presented as n(%).
ARZ allergic rhinitis.diagnosis of asthma was made. In many patients in our
study, nasal symptoms occur before increased bronchial
sensitivity and bronchial symptoms of asthma. This is
consistent with reports in the literature and reflects the
comorbid nature of these disorders.7
Among 524 patients with concomitant asthma and AR, 44
patients (8.4%) were not diagnosed with AR, although the
patients reported AR symptoms. Moreover, nearly 40% of
patients did not treat their AR at all. This suggests that the
asthma management guidelines are not being adequately
put in practice by physicians and patients. This result agrees
with those of recent studies, which report unawareness and
undertreatment of AR comorbid with BA.16 Indeed, the
Global Initiative for Asthma guidelines disclosed that
“special considerations” are required in managing asthma
coexistent with AR, and treatment of AR may improve
asthma symptoms.17,18 But, the guidelines offer no further
recommendations, such as examination of the nose or asking
the patient whether or how AR worsens their asthma. The
ARIA guidelines were the first to stress the connection
between AR and asthma.17 It is recommended to evaluate
patients with persistent AR for asthma and to evaluate
patients with asthma for rhinitis. A “combined strategy” to
treat the upper and lower airways is advised.9 Hence, to
achieve better control of asthma, awareness of this
“combined strategy” needs to be heightened among physi-
cians and incorporated by the primary care into daily clinical
practice.
There are two limitations that need to be addressed
regarding the present study. The first limitation concerns
the cross-sectional nature of this research project, which
has focused on prevalence of AR in asthma patients instead
of the burden of asthmatic patients. The second limitation
has to do with subjects who were enrolled from chest
department and all investigators are chest specialist in
those hospitals. Therefore, the findings of treatment
distribution and clinical characteristics in present study
cannot be overemphasized beyond the epidemiologic study.tients
524) Without AR (nZ 226) Total (nZ 750)
24 (10.7) 350 (46.7)
23 (95.8) 244 (69.7)
1 (4.2) 79 (22.6)
0 (0.0) 25 (7.1)
0 (0.0) 2 (0.6)
20 (83.3) 219 (62.6)
2 (8.3) 104 (29.7)
0 (0.0) 64 (18.3)
0 (0.0) 50 (14.3)
1 (4.2) 13 (3.7)
0 (0.0) 15 (4.3)
0 (0.0) 1 (0.3)
1 (4.2) 0 (0.0)
1 (4.2) 18 (5.1)
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